125 related articles for article (PubMed ID: 27980025)
1. Individualized Tamoxifen Dose Escalation-Response.
Hertz DL; Rae JM
Clin Cancer Res; 2016 Dec; 22(24):6301. PubMed ID: 27980025
[No Abstract] [Full Text] [Related]
2. Individualized Tamoxifen Dose Escalation-Letter.
Koolen SL; Bins S; Mathijssen RH
Clin Cancer Res; 2016 Dec; 22(24):6300. PubMed ID: 27980024
[No Abstract] [Full Text] [Related]
3. Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility.
Hertz DL; Rae JM
Clin Cancer Res; 2016 Jul; 22(13):3121-3. PubMed ID: 27012810
[TBL] [Abstract][Full Text] [Related]
4. CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.
Dezentjé VO; Opdam FL; Gelderblom H; Hartigh den J; Van der Straaten T; Vree R; Maartense E; Smorenburg CH; Putter H; Dieudonné AS; Neven P; Van de Velde CJ; Nortier JW; Guchelaar HJ
Breast Cancer Res Treat; 2015 Oct; 153(3):583-90. PubMed ID: 26369533
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
6. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.
Chang SM; Barker FG; Huhn SL; Nicholas MK; Page M; Rabbitt J; Prados MD
J Neurooncol; 1998 Apr; 37(2):169-76. PubMed ID: 9524096
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs.
Waddle JR; Fine RL; Case BC; Trogdon ML; Tyczkowska K; Frazier D; Page RL
Cancer Chemother Pharmacol; 1999; 44(1):74-80. PubMed ID: 10367752
[TBL] [Abstract][Full Text] [Related]
8. Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.
Fox P; Balleine RL; Lee C; Gao B; Balakrishnar B; Menzies AM; Yeap SH; Ali SS; Gebski V; Provan P; Coulter S; Liddle C; Hui R; Kefford R; Lynch J; Wong M; Wilcken N; Gurney H
Clin Cancer Res; 2016 Jul; 22(13):3164-71. PubMed ID: 26847054
[TBL] [Abstract][Full Text] [Related]
9. Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
Thakkar SG; Peereboom D; Olencki T; Jacobs B; Elson P; Rybicki L; Lindner DJ; Borden EC
J Interferon Cytokine Res; 2006 Nov; 26(11):800-3. PubMed ID: 17115898
[TBL] [Abstract][Full Text] [Related]
10. Controversies regarding tamoxifen and uterine carcinoma.
Neven P; Vergote I
Curr Opin Obstet Gynecol; 1998 Feb; 10(1):9-14. PubMed ID: 9484623
[TBL] [Abstract][Full Text] [Related]
11. High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma.
O'Day SJ; Boasberg PD; Kristedja TS; Martin M; Wang HJ; Fournier P; Cabot M; DeGregorio MW; Gammon G
Cancer; 2001 Aug; 92(3):609-19. PubMed ID: 11505406
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-induced thrombocytopenia.
Yao JC; Thomakos N; McLaughlin P; Buchholz TA; Kudelka AP
Am J Clin Oncol; 1999 Oct; 22(5):529-32. PubMed ID: 10521073
[TBL] [Abstract][Full Text] [Related]
13. Malignant glioma sensitivity to radiotherapy, high-dose tamoxifen, and hypericin: corroborating clinical response in vitro: case report.
Zhang W; Hinton DR; Surnock AA; Couldwell WT
Neurosurgery; 1996 Mar; 38(3):587-90; discussion 590-1. PubMed ID: 8837815
[TBL] [Abstract][Full Text] [Related]
14. Should tamoxifen users be screened for endometrial lesions?
Neven P; Vergote I
Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
[No Abstract] [Full Text] [Related]
15. Enhancing the solubility and bioactivity of anticancer drug tamoxifen by water-soluble pillar[6]arene-based host-guest complexation.
Shangguan L; Chen Q; Shi B; Huang F
Chem Commun (Camb); 2017 Aug; 53(70):9749-9752. PubMed ID: 28812763
[TBL] [Abstract][Full Text] [Related]
16. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer
.
Klopp-Schulze L; Joerger M; Wicha SG; Parra-Guillen ZP; Kloft C
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):690-691. PubMed ID: 27641215
[No Abstract] [Full Text] [Related]
17. Individualization of tamoxifen treatment for breast carcinoma.
Binkhorst L; van Gelder T; Mathijssen RH
Clin Pharmacol Ther; 2012 Oct; 92(4):431-3. PubMed ID: 22910442
[TBL] [Abstract][Full Text] [Related]
18. Secretory endometrial adenocarcinoma in a tamoxifen user with breast cancer after menopause.
Wu CJ; Peng YJ; Yu MH; Chen CH
Taiwan J Obstet Gynecol; 2007 Mar; 46(1):88-90. PubMed ID: 17389201
[No Abstract] [Full Text] [Related]
19. Evolving uses of hormonal agents for breast cancer therapy.
Cummings FJ
Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
[TBL] [Abstract][Full Text] [Related]
20. Sunny outlook for personalized medicine: tamoxifen and beyond.
Teft WA; Kim RB
Pharmacogenomics; 2013 Oct; 14(13):1533-6. PubMed ID: 24088122
[No Abstract] [Full Text] [Related]
[Next] [New Search]
